>
Active Shooter in Tactical Gear Storms Border Patrol Station in Texas--Cops Neutralize Attacker
Benjamin Franklin and the Self-Made Man: Making America
SHOCK REPORT: DOJ, FBI Review Finds NO Jeffrey Epstein 'Client List,' Confirms Suicide - SF6
FBI Concludes Jeffrey Epstein Had No Clients, Didn't Blackmail Anyone, And Definitely Killed Him
Insulator Becomes Conducting Semiconductor And Could Make Superelastic Silicone Solar Panels
Slate Truck's Under $20,000 Price Tag Just Became A Political Casualty
Wisdom Teeth Contain Unique Stem Cell That Can Form Cartilage, Neurons, and Heart Tissue
Hay fever breakthrough: 'Molecular shield' blocks allergy trigger at the site
AI Getting Better at Medical Diagnosis
Tesla Starting Integration of XAI Grok With Cars in Week or So
Bifacial Solar Panels: Everything You NEED to Know Before You Buy
INVASION of the TOXIC FOOD DYES:
Let's Test a Mr Robot Attack on the New Thunderbird for Mobile
Facial Recognition - Another Expanding Wolf in Sheep's Clothing Technology
The artificial heart was developed by a French company, CARMAT and has been approved for use and sale in Europe.
Last year, the company received U.S. FDA approval to begin studies and enroll 10 patients with end-stage biventricular heart failure—people who are suffering on the waiting list for a heart donor—and offer a life-saving bridge before transplant.
"We are encouraged that our patient is doing so well after the procedure Monday," said Dr. Carmelo Milano, a transplant surgeon and the principal investigator of the device study at Duke. "As we evaluate this device, we are both excited and hopeful that patients who otherwise have few to no options could have a lifeline."
The North Carolina patient, Matthew Moore, is just 39-years-old and was referred to Duke in June after a sudden, unexpected diagnosis of heart failure. Moore and his wife, Rachel, recently adopted their two-year-old foster son, Marshall, and arrived at Duke expecting only to undergo heart bypass surgery.